Arca
Skip to content
Tools
Tools

Hodgkin lymphoma

Drug research and approvals for hodgkin lymphoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 1,016 studies of hodgkin lymphoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 24 drug trials for it since 2013, FDA has 9 approved and 3 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 1,016
  • Trials authorized in Canada: 24
  • FDA orphan approvals: 9
  • EU medicines: 1

Recruiting now

Newest posted first, of 1,016 recruiting on ClinicalTrials.gov ↗

How its trials ended

818 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 242 whose ending is known, 48% met their primary endpoint, 3% missed it and 50% stopped early.

  • Completed, result not reported33140%
  • Ongoing17822%
  • Met its primary endpoint11514%
  • Status unknown678%
  • Stopped: other or unclear547%
  • Stopped: enrollment or feasibility354%
  • Stopped: sponsor or business decision182%
  • Missed its primary endpoint71%
  • Stopped: funding71%
  • Stopped: lack of efficacy51%
  • Stopped: safety1<1%

Trials authorized in Canada

The 10 newest of 24; search them all in Canada trials
May 14, 2024Norm: nodular lymphocyte-predominant Hodgkin lymphoma patients treated in a randomized phase 2 trial with either rituximab or mosunetuzumabMosunetuzumab (nsc 833090)Dr. Anca PricaOngoing
Jul 20, 2023A randomized phase 3 interim response adapted trial comparing standard therapy with immuno-oncology therapy for children and adults with newly diagnosed stage…Nivolumab / Brentuximab vedotin / Etoposide phosphateChildrens Oncology GroupOngoing
May 25, 2023A randomised phase III trial with a pet response adapted design comparing abvd +/- isrt with A2VD +/- isrt in patients with previously untreated stage ia/iia…AdcetrisCanadian Cancer Trials Group, Cancer Research Institute, Queen's UniversityOngoing
Apr 5, 2023A phase 3 randomized clinical study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) versus physician's choice chemotherapy in…MK-4280A (favezelimab (MK-4280)-pembrolizumab (MK-3475))Merck & Co. (MSD)Ongoing
Mar 3, 2022A phase 1, open-label, dose-escalation and dose-expansion study of NL-201 in patients with B-cell lymphoma, Hodgkin lymphoma, or multiple myelomaNL-201Neoleukin Therapeutics Inc.Pending
Jan 21, 2022A randomized phase II trial of pembrolizumab and brentuximab vedotin versus gdp followed by high dose chemotherapy and autologous stem cell transplantation for…Adcetris / KeytrudaCanadian Cancer Trials Group, Cancer Research Institute, Queen's UniversityOngoing
Jan 10, 2022"a phase I/II open-label, multi-center study to assess safety, tolerability, pharmacokinetics and preliminary efficacy of AZD7789, an ANTI-PD-1 and ANTI-TIM-3…AZD7789AstraZeneca PharmaceuticalsClosed
Aug 12, 2021Phase 2 study of pembrolizumab and chemotherapy in patients with newly diagnosed classical Hodgkin lymphoma (keynote-C11)Pembrolizumab (MK-3475)Merck & Co. (MSD)Ongoing
May 19, 2021A phase 2 study of pembrolizumab (MK-3475) every 6 weeks (Q6W) in participants with relapsed or refractory classical Hodgkin's lymphoma (RRCHL) or relapsed or…KeytrudaMerck & Co. (MSD)Ongoing
Dec 14, 2020Multiple part clinical trial of brentuximab vedotin in classical Hodgkin lymphoma subjectsAdcetris (brentuximab vedotin)PfizerPending

FDA orphan designations

Approved first, then open designations, newest first
Mar 20, 2026OpdivoIn combination with doxorubicin, vinblastine, and dacarbazine (AVD), for the treatment of adult and pediatric patients 12 years and older…Bristol-Myers Squibb CompanyApproved
Nov 10, 2022AdcetrisTreatment of pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL) in combination with…Seagen Inc.Approved
Oct 14, 2020KeytrudaTreatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL); and treatment of pediatric patients with…MSD International Business GmbHApproved
Mar 20, 2018AdcetrisADCETRIS® is indicated for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in…Seagen Inc.Approved
Apr 25, 2017OpdivoTreatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell…Bristol-Myers Squibb CompanyApproved
Mar 14, 2017KeytrudaTreatment for adult and pediatric patients with refractory classical Hodgkin Lymphoma (cHL), or who have relapsed after 3 or more prior…MSD International Business GmbHApproved
May 17, 2016OpdivoTreatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell…Bristol-Myers Squibb CompanyApproved
Aug 17, 2015AdcetrisTreatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell…Seagen Inc.Approved
Aug 19, 2011AdcetrisThe treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two…Seagen Inc.Approved
Apr 29, 2015(S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-met…Treatment of Hodgkin lymphomaIncyte CorporationDesignated
Aug 20, 2009Recombinant antibody construct against human CD30 and CD16ATreatment of Hodgkin lymphomaAffimed GmbHDesignated
Dec 2, 2008Anti-CD30 Fc engineered humanized monoclonal antibodyTreatment of Hodgkin lymphomaXencor, Inc.Designated

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Oct 25, 2012AdcetrisBrentuximab vedotinTakeda Pharma A/SEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.